PILA PHARMA AB
Pila Pharma AB is a clinical stage biotech company developing a potent, selective TRPV1 antagonist, XEN-D0501, as treatment of type 2 diabetes, obesity and the rare painful disease erythromelalgia. XEN-D0501 has been tested in 300 subjects in phase 1 and 2 and has a demonstrated good safety profile in healthy volunteers and in patients with overactive bladder disease, chronic cough or type 2 diabetes as well as efficacy in type 2 diabetics on improving glucose stimulated insulin secretion. Rec... ently, 13 week preclinical safety studies with XEN-D0501 completed without registration of side effects and the molecule can therefore progress to clinical trials of up to 3 months duration. In July 2022, the company received US Orphan Drug Designation for XEN-D0501 as treatment as the rare and painful disease erythromelalgia. The company is based in Malmö, Sweden and is listed on Nasdaq First North GM, Stockholm, since July 2021.
PILA PHARMA AB
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
2014-01-20
Address:
Malmö, Skane Lan, Sweden
Country:
Sweden
Website Url:
http://www.pilapharma.com
Total Employee:
1+
Status:
Active
Contact:
+4528606383
Email Addresses:
[email protected]
Total Funding:
5.18 M USD
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta SPF Apple Mobile Web Clips Icon Google Font API Google Tag Manager WordPress Google Analytics LetsEncrypt SSL By Default
Similar Organizations
Arctic Therapeutics
Arctic Therapeutics (AT) uses bioinformatic approaches and AI to eliminate major risks associated with traditional drug development.
Aro Biotherapeutics
Aro Biotherapeutics develops tissue-targeted genetic medicines using Centyrins, a proprietary technology, to address complex diseases.
CStone Pharmaceuticals
CStone Pharmaceuticals is a bio-pharmaceutical company develops new treatments in a range of therapeutic areas.
Eden Biologics
Eden Biologics is a biopharmaceutical company that develops biosimilars and accelerates the development programs for clients & partners.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Pinpoint Therapeutics
Pinpoint Therapeutics is a preclinical stage company developing novel cancer treatment options aimed to specifically inhibit autophagy.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
EASME - EU Executive Agency for SMEs
EASME - EU Executive Agency for SMEs investment in Grant - Pila Pharma AB
Almi Invest
Almi Invest investment in Pre Seed Round - Pila Pharma AB
Dorte Xenia Gram
Dorte Xenia Gram investment in Pre Seed Round - Pila Pharma AB
Official Site Inspections
http://www.pilapharma.com
- Host name: linux10.dandomain.dk
- IP address: 93.191.158.14
- Location: Langeskov Denmark
- Latitude: 55.3565
- Longitude: 10.5845
- Timezone: Europe/Copenhagen
- Postal: 5550
More informations about "Pila Pharma AB"
Pila Pharma AB - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number +4528606383 Pila Pharma AB is a clinical stage biotech company developing a potent, selective TRPV1 antagonist, XEN-D0501, as …See details»
Press release - Pila Pharma
Malmö, 21 November 2024. PILA PHARMA AB (publ) (“PILA PHARMA” or the “Company”) today announces the initiation of the study associated to the co-sponsorship of the research collaboration with the Research Group of …See details»
PILA PHARMA - Home
Address Medeon AB Medeon Science Park 205 12 MALMÖ. Find us. Phone: 040-32 10 00 Fax: Find us E-mail: [email protected]. About this siteSee details»
Pila Pharma AB (publ) (STO:PILA) Company Profile & Overview
Mar 6, 2025 PILA PHARMA AB (publ) operates as a clinical stage pharmaceutical company in Sweden. It is developing XEN-D0501, a TRPV1 antagonist that has completed two phase 2b …See details»
Pila Pharma - Pharmaceutical Companies Database - ICH GCP
Locations, phone, website - all information about Pila PharmaSee details»
PPadmin - Pila Pharma
Malmö, 22 April, 2022. Download the press release as PDF here. Pila Pharma AB announces that the company has submitted a request for an Orphan Drug Designation to the U.S. Food and …See details»
PILA PHARMA | LinkedIn
PILA PHARMA | 1,430 followers on LinkedIn. We are a #TRPV1 focused company developing oral treatments for Type-2 #Diabetes & #Erythromelalgia | PILA PHARMA is a publicly held …See details»
Pila Pharma - Craft
Pila Pharma has 5 employees at their 1 location. See insights on Pila Pharma including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Pila Pharma - Inderes
Pila Pharma operates in the pharmaceutical industry. The company conducts clinical trials in phase 2 with pharmaceuticals for type 2 diabetes. The main product is a tablet that is taken …See details»
Pila Pharma builds pipeline - applies for Orphan Drug Designation …
Pilapharma.com Malmö, 22 April, 2022 Pila Pharma builds pipeline - applies for Orphan Drug Designation in the USA Pila Pharma AB announces that the company has submitted a request …See details»
Pila Pharma AB (publ) (PILA.ST) - Yahoo Finance
Find the latest Pila Pharma AB (publ) (PILA.ST) stock quote, history, news and other vital information to help you with your stock trading and investing.See details»
Pila Pharma AB (publ) Company Information - Simply Wall St
Learn more about Pila Pharma AB (publ) (5KC). From their employee growth over the years and their exchange listings.See details»
Pila Pharma AB, PILA:STO profile - FT.com - Financial Times
Feb 19, 2025 Pila Pharma AB (PILA:STO) company profile with history, revenue, mergers & acquisitions, peer analysis, institutional shareholders and more.See details»
Pila Pharma AB publishes annual report for 2022
Title: Microsoft Word - 230426_Final_Financial Year Report 2022 ENG_PILA PHARMA.docx Created Date: 4/26/2023 6:10:13 AMSee details»
PILA PHARMA on LinkedIn: #ceo #pila #investment #biotech …
This morning, we've released our first half-year report for 2024! Please find the latest comments from our #CEO Gustav Hanghøj Gram on the status, progress…See details»
Nobel prize for the discovery of PILA PHARMA´s leading principle
Pilapharma.com Malmö, Sweden, October 5, 2021 Nobel prize for the discovery of PILA PHARMA´s leading principle On Monday, October 4, the Nobel Assembly at Karolinska …See details»
Regulatoriska pressmeddelanden - pilapharma.com
Malmö, Sweden, April 25, 2022. Download the press release as PDF here. Pila Pharma AB (PILA) today announces that the study material (non-GMP API) to be used in three-month …See details»
5KC Stock Price Quote - Morningstar
See the latest Pila Pharma AB stock price (5KC:XFRA), related news, valuation, dividends and more to help you make your investing decisions.See details»
PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH …
Pilapharma.com Malmö, 26 November 2023 PILA PHARMA ANNOUNCES PRECLINICAL RESEARCH COLLABORATION Pila Pharma AB (publ) (“Pila Pharma” or the “Company”) has …See details»
Malmö, 11 June 2024 - pilapharma.com
Pilapharma.com Malmö, 11 June 2024 PILA PHARMA PRESENTS TOMORROW AT ”AKTIESPARARNA” PILA PHARMA AB (publ) (FN STO: PILA) announces that it will present …See details»